相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Catherine J. Lee et al.
BONE MARROW TRANSPLANTATION (2019)
Measurable residual disease testing for personalized treatment of acute myeloid leukemia
Mats Ehinger et al.
APMIS (2019)
Taking a BiTE out of ALL: blinatumomab approval for MRD-positive ALL
Emily Curran et al.
BLOOD (2019)
The emerging role of measurable residual disease detection in AML in morphologic remission
F. Buccisano et al.
SEMINARS IN HEMATOLOGY (2019)
Genetic and epigenetic determinants of AML pathogenesis
Sheng F. Cai et al.
SEMINARS IN HEMATOLOGY (2019)
Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia
Ross L. Levine et al.
HAEMATOLOGICA (2019)
Peripheral blood minimal/measurable residual disease assessed in flow cytometry in acute myeloblastic leukemia
Cecile Guenot et al.
LEUKEMIA (2019)
Can we incorporate MRD assessment into clinical practice in AML?
Gert Ossenkoppele et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2019)
New Targeted Agents in Acute Myeloid Leukemia: New Hope on the Rise
Stephan R. Bohl et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Digital PCR in Myeloid Malignancies: Ready to Replace Quantitative PCR?
Daniela Cilloni et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
ClonoSEQ assay for the detection of lymphoid malignancies
Anna Monter et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2019)
Induction response criteria in acute myeloid leukaemia: implications of a flow cytometric measurable residual disease negative test in refractory adults
Sylvie D. Freeman et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia
S. Modvig et al.
LEUKEMIA (2019)
CD34+CD38- leukemic stem cell frequency to predict outcome in acute myeloid leukemia
Wendelien Zeijlemaker et al.
LEUKEMIA (2019)
Morphological and Immunophenotypic Clues to the WHO Categories of Acute Myeloid Leukaemia
Barbara J. Bain et al.
ACTA HAEMATOLOGICA (2019)
Innovation in Flow Cytometry Analysis: A New Paradigm Delineating Normal or Diseased Bone Marrow Subsets Through Machine Learning
Francis Lacombe et al.
HEMASPHERE (2019)
Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia
Francis Lacombe et al.
HEMATOLOGICAL ONCOLOGY (2018)
Minimal residual disease analysis in myeloma - when, why and where
Uday Yanamandra et al.
LEUKEMIA & LYMPHOMA (2018)
Wilms' Tumor 1 Gene Expression Using a Standardized European LeukemiaNet-Certified Assay Compared to Other Methods for Detection of Minimal Residual Disease in Myelodysplastic Syndrome and Acute Myelogenous Leukemia after Allogeneic Blood Stem Cell Transplantation
Christina Rautenberg et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
Gerrit J. Schuurhuis et al.
BLOOD (2018)
Minimal residual disease in chronic lymphocytic leukemia: A consensus paper that presents the clinical impact of the presently available laboratory approaches
Ciprian Tomuleasa et al.
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES (2018)
Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia
Kiyomi Morita et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia
Maja Rothenberg-Thurley et al.
LEUKEMIA (2018)
Molecular Minimal Residual Disease in Acute Myeloid Leukemia
M. Jongen-Lavrencic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Jacqueline Cloos et al.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2018)
Hematopoietic cell transplantation as treatment of patients with acute myeloid leukemia with measurable residual disease after consolidation therapy
Frederick R. Appelbaum
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2018)
Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML
Felicitas Thol et al.
BLOOD (2018)
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial
Uwe Platzbecker et al.
LANCET ONCOLOGY (2018)
Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse
TaeHyung Kim et al.
BLOOD (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia
F. Buccisano et al.
BONE MARROW TRANSPLANTATION (2017)
Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia
Fabio Guolo et al.
HAEMATOLOGICA (2017)
Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis
Sarah A. Buckley et al.
HAEMATOLOGICA (2017)
Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group
Marie Balsat et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia
Carolyn Owen et al.
LEUKEMIA & LYMPHOMA (2017)
Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia
Fabio Guolo et al.
HAEMATOLOGICA (2017)
Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis
Sarah A. Buckley et al.
HAEMATOLOGICA (2017)
Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia AMeta-analysis
Donald A. Berry et al.
JAMA ONCOLOGY (2017)
Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation
Monika Brueggemann et al.
BLOOD ADVANCES (2017)
Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia
Brittany Knick Ragon et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stern Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia
Chen-Hua Yan et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance
David Grimwade et al.
BLOOD (2016)
A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia
W. Zeijlemaker et al.
LEUKEMIA (2016)
Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia
W. Zeijlemaker et al.
LEUKEMIA (2016)
Myeloablative, but not Reduced-Intensity, Conditioning Overcomes the Negative Effect of Flow-Cytometric Evidence of Leukemia in Acute Myeloid Leukemia
Celalettin Ustun et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia
M. Othus et al.
LEUKEMIA (2016)
Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia
Y. Zhou et al.
LEUKEMIA (2016)
Cord-Blood Transplantation in Patients with Minimal Residual Disease
Filippo Milano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Assessment of Minimal Residual Disease in Standard-Risk AML
A. Ivey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Monitoring minimal residual disease in acute myeloid leukaemia: a review of the current evolving strategies
Hans Beier Ommen
THERAPEUTIC ADVANCES IN HEMATOLOGY (2016)
Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia
Lynn Quek et al.
BLOOD ADVANCES (2016)
Follow-up of post-transplant minimal residual disease and chimerism in childhood lymphoblastic leukaemia: 90 d to react
Cecile Pochon et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation
R. B. Walter et al.
LEUKEMIA (2015)
MRD in AML: It is time to change the definition of remission
Gert J. Ossenkoppele et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2014)
Leukemic Stem Cell Frequency: A Strong Biomarker for Clinical Outcome in Acute Myeloid Leukemia
Monique Terwijn et al.
PLOS ONE (2014)
MRD in AML: time for redefinition of CR?
Gert Ossenkoppele et al.
BLOOD (2013)
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia
Eric Jourdan et al.
BLOOD (2013)
Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission
Roland B. Walter et al.
BLOOD (2013)
Leukaemia relapse after allogeneic transplants for acute myeloid leukaemia: predictive role of WT1 expression
Sarah Pozzi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study
Monique Terwijn et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial
John A. Liu Yin et al.
BLOOD (2012)
Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group
Jan Kroenke et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Modern Therapy of Acute Lymphoblastic Leukemia
Renato Bassan et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia
Roland B. Walter et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine
Costa Bachas et al.
BLOOD (2010)
Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized WT1 Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study
Daniela Cilloni et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy
David Grimwade et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Donor lymphocyte infusion in the treatment of first Hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia:: A retrospective risk factors analysis and comparison with other strategies by the EBMT acute leukemia working party
Christoph Schmid et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations
P. Gorello et al.
LEUKEMIA (2006)
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.
B Falini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Preemptive treatment of minimal residual disease post transplant in CML using real-time quantitative RT-PCR: a prospective, randomized trial
YJ Kim et al.
BONE MARROW TRANSPLANTATION (2004)
分享论文
